Neuro-SysMed Seminar April 22, 2026
Welcome to the Neuro-SysMed monthly seminar series! Join us at the auditorium in Armauer Hansens Hus at 11:30 - 13:00 (lunch from 11:30 - 12:00). The topic this time is presented by Neuro-SysMed's ALS Node.
Main content
Speakers
Ole-Bjørn Tysnes og Mari Klauset Holtom from Neuro-SysMed's ALS Node (external link).
Topic
"Challenges in running a multicentre RCT. The NO-ALS study experience."
Registration
Registration through this link (external link). The deadline if you'd like to join the lunch is April 20 at 11.00.
Where and when
Place: The auditorium in Armauer Hansens Hus
When: April 22, 2026, at 11:30 - 13:00 (lunsj 11:30 - 12:00).
Abstract
There are currently no neuroprotective treatments for Amyotrophic lateral sclerosis (ALS) with a significant impact on disease progression. Previous research by the PD Node and others has nominated NAD-replenishment therapy as a promising neuroprotective strategy against neurodegeneration. Moreover, prior to the NO-ALS study, a published small trial using a combination of the NAD-precursor nicotinamide riboside (NR) and sirtuin booster pterostilbene, showed encouraging findings in ALS. To test the potential of this strategy as a neuroprotective therapy for ALS, Neuro-SysMed Centre for Clinical Treatment Research initiated the NO-ALS trial, a phase-II, multicentre, double-blinded randomized trial of oral NR and pterostilbene inn early ALS. At this seminar, Professor Ole-Bjørn Tysnes and Study Nurse Mari Klauset Holtom from Neuro-SysMed's ALS node will discuss experiences from the NO-ALS trial, and discuss challenges in running a multicentre randomized clinical trial.